… survival in this setting. Our findings support pembrolizumab as a potential new treatment
option for patients with stage IB, II, or IIIA NSCLC … Lung cancer-specific survival was defined as …

… mortality worldwide. Despite numerous advances in treatments over the past decade, non-small
cell lung cancer … were alive without disease recurrence in the surgery arm at five years.…

… Early stage non–small cell lung cancer (NSCLC) manifests as two radiologic subtypes on …
with favorable survival outcomes, despite the size of the solid component and clinical stage (2–…

… A landmark meta-analysis in 1998 showed that postoperative radiotherapy (PORT) was
adversely associated with the survival of patients with non–small cell lung cancer (NSCLC). This …

… in patients with advanced non–small cell lung cancer treated … BMI and survival in patients
with advanced NSCLC treated … BMI and survival outcomes of patients initiating atezolizumab …

… For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive
up to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease. …

… in progression-free survival in patients with unresectable stage III NSCLC without disease
progression after concurrent or sequential chemoradiotherapy, compared with placebo. …

… patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations. A
guideline update for patients with stage IV NSCLC … 2-year survival improvement for patients with …

… endpoints of overall survival and progression-free survival in patients with PD-L1 of at least
1% were analysed descriptively at the interim and final progression-free survival analyses. …

… -year relative survival among patients with lung cancer according to sex, subtype, and calendar
year, using the relative survival … treatment of metastatic non-small cell lung cancer. J Natl …